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Abstract
Background: Recently we reported that activation of Epac1, an exchange protein activated by cAMP, increases
melanoma cell migration via Ca
2+ release from the endoplasmic reticulum (ER). G-protein bg subunits (Gbg)a r e
known to act as an independent signaling molecule upon activation of G-protein coupled receptor. However, the
role of Gbg in cell migration and Ca
2+ signaling in melanoma has not been well studied. Here we report that
there is crosstalk of Ca
2+ signaling between Gbg and Epac in melanoma, which plays a role in regulation of cell
migration.
Methods: SK-Mel-2 cells, a human metastatic melanoma cell line, were mainly used in this study. Intracellular Ca
2+
was measured with Fluo-4AM fluorescent dyes. Cell migration was examined using the Boyden chambers.
Results: The effect of Gbg on Epac-induced cell migration was first examined. Epac-induced cell migration was
inhibited by mSIRK, a Gbg -activating peptide, but not its inactive analog, L9A, in SK-Mel-2 cells. Guanosine 5’, a-b-
methylene triphosphate (Gp(CH2)pp), a constitutively active GTP analogue that activates Gbg, also inhibited Epac-
induced cell migration. In addition, co-overexpression of b1 and g2, which is the major combination of Gbg, inhibited
Epac1-induced cell migration. By contrast, when the C-terminus of b adrenergic receptor kinase (bARK-CT), an
endogenous inhibitor for Gbg, was overexpressed, mSIRK’s inhibitory effect on Epac-induced cell migration was
negated, suggesting the specificity of mSIRK for Gbg. We next examined the effect of mSIRK on Epac-induced Ca
2+
response. When cells were pretreated with mSIRK, but not with L9A, 8-(4-Methoxyphenylthio)-2’-O-methyladenosine-
3’,5’-cyclic monophosphate (8-pMeOPT), an Epac-specific agonist, failed to increase Ca
2+ signal. Co-
overexpression of b1a n dg2 subunits inhibited 8-pMeOPT-induced Ca
2+ elevation. Inhibition of Gbg with bARK-
CT or guanosine 5’-O-(2-thiodiphosphate) (GDPbS), a GDP analogue that inactivates Gbg, restored 8-pMeOPT-
induced Ca
2+ elevation even in the presence of mSIRK. These data suggested that Gbg inhibits Epac-induced
Ca
2+ elevation. Subsequently, the mechanism by which Gbg inhibits Epac-induced Ca
2+ elevation was
explored. mSIRK activates Ca
2+ influx from the extracellular space. In addition, W-5, an inhibitor of calmodulin,
abolished mSIRK’s inhibitory effects on Epac-induced Ca
2+ elevation, and cell migration. These data suggest
that, the mSIRK-induced Ca
2+ from the extracellular space inhibits the Epac-induced Ca
2+ release from the ER,
resulting suppression of cell migration.
Conclusion: We found the cross talk of Ca
2+ signaling between Gbg and Epac, which plays a major role in
melanoma cell migration.
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Melanoma causes the majority of skin cancer related
death, and is prevalent worldwide. The median life span
of patients with advanced stage melanoma is less than a
year because no therapies are effective once the tumor
has spread to vital organs [1]. The tumor metastasis
process is conventionally understood as the migration of
individual cells that detach from the primary tumor,
enter lymphatic vessels or the bloodstream, attach to
endothelial cells and undergo transendothelial extravasa-
tion, and proliferate in organs [2]. Although numerous
efforts have been focused on understanding of mela-
noma progression, the controlling of melanoma cell
migration/metastasis has been unsuccessful.
G protein-coupled receptors (GPCRs) belong to a
large family of transmembrane receptors. Upon ligand
binding, the G-protein a and bg subunits (Ga and
Gbg, respectively) are dissociated. Each molecule regu-
lates intracellular signal transductions and evokes cel-
lular responses including cell migration [3]. Previous
reports suggested a role of Gbg in cell migration of
endothelial cells and breast cancer cells [4-6]; however,
the role of Gbg in melanoma is largely unknown. Gbg
is also known to regulate Ca
2+ homeostasis via regula-
tion of membrane voltage-dependent Ca
2+ channels in
excitable cells [7,8]. In non-excitable cells, Gbg acti-
vates Ca
2+ release from the endoplasmic reticulum
(ER) [9,10]. However, the role of Gbg in Ca
2+ signal-
ing in cancer cells, including melanoma, remains
unknown.
In addition to the traditional target of cAMP, protein
kinase A (PKA), a new, PKA-independent signaling
pathway has been identified. The exchange protein
directly activated by cAMP (Epac), a guanine nucleotide
exchange factor [11], has two isoforms, Epac1 and
Epac2. Epacs mediate cAMP signaling through activa-
tion of a small-molecular-weight G protein, Rap1 [12].
Previous reports demonstrated functions of Epac in can-
cer cells. Epac mediates cell adhesion in Ovcar3 cells
[13], apoptosis and growth arrest [14] in B lymphoma
cells, formation of embryonic vasculogenic networks in
melanoma cells [16], and proliferation of prostate carci-
noma cells [15]. Previously, we have reported that Epac
increases melanoma cell migration by modification of
heparan sulfate, a major component of the extracellular
matrix [17]. More recently, we demonstrated that Epac
increases cytosolic Ca
2+ in melanoma cells, which also
led to an increase of cell migration. The major mechan-
ism in Epac-induced Ca
2+ elevation was activation of
inositol triphosphate (IP3) receptor to release Ca
2+
from the ER [18]. Although calmodulin is a major regu-
lator of IP3 receptors [19-21], the role of calmodulin in
melanoma is still unclear.
In the present study, we demonstrated that there is
interaction between Ca
2+ signaling between Gbg and
Epac in melanoma. The interaction evoked by Gbg
inhibited Epac-induced Ca
2+ elevation and cell migra-
tion via additional Ca
2+ influx from the extracellular
space. We thus propose that Gbg-signaling inhibits the
Epac-induced cell migration via a Ca
2+-dependant
mechanism in melanoma.
Methods
Reagents and cell lines
Reagents were purchased from Sigma unless otherwise
specified. G-protein bg activating peptide, myr-SIRKAL-
NILGYPDYD-OH (mSIRK), and its control peptide,
myr-SIRKALNIAGYPDYD-OH (L9A), 2-aminoethoxydi-
phenyl borate (2-APB), xestopongin C, ryanodine, N-
(6-aminohexyl)-1-naphthalenesulfonamide (W-5) were
purchased from EMD Chemicals. Guanosine 5’, a-,b-
methylene, triphosphate (Gp(CH2)pp) was purchased
from Biomol International. 8-(4-Methoxyphenylthio)-
2’-O-methyladenosine-3’,5’-cyclic monophosphate (8-
pMeOPT) was purchased from Biolog. Antibodies
against Epac1, Gb1, Gg2, C-terminal domain of b-adre-
nergic receptor kinase (bARK-CT) were purchased
from Santa Cruz Biotechnology. Anti-a-tubulin anti-
body was purchased from Abcam. SK-Mel-2 and SK-
Mel-24 melanoma cell lines were obtained from the
American Type Culture Collection. SK-Mel-187 cell
line was kindly provided by Dr. Alan Houghton. C8161
cell line was provided by Dr. Mary JC Hendrix.
WM1552C, WM115, WM3248, WM1361A were
obtained from Dr. Meenhard Herlyn. SK-Mel-2 and
SK-Mel-24 cells were maintained in MEM containing
10% FBS, 1% penicillin-streptomycin. All other mela-
noma cells were maintained in RPMI containing 10%
FBS, 1% penicillin-streptomycin.
Fluorescence imaging of intracellular Ca
2+
Measurement of intracellular Ca
2+ release was per-
formed as we previously described [18]. Cells were incu-
bated with HEPES buffer containing 4 μmol/L of Fluo-
4AM followed by washing and incubation with HEPES
buffered saline containing 1.8 mmol/L of CaCl2.A n
iXon+ 885 charge-coupled device camera (Andor Tech-
nology) was used to monitor fluorescence changes. Full
images were collected every 4 seconds. The field was
illuminated by two wavelengths in rapid succession.
Fluo-4 was excited at 488 nm, and data were expressed
as normalized changes in background-corrected fluores-
cence emission (F/F0). Data were analyzed using Ima-
ging Workbench (INDEC BioSystems). Representative
Ca
2+ signals averaged from 5 individual cells were
shown in the figures.
Baljinnyam et al. BMC Cancer 2011, 11:256
http://www.biomedcentral.com/1471-2407/11/256
Page 2 of 9Western blot analysis
Western blot analysis was performed as we previously
described [22,23]. Briefly, cells were lysed and sonicated
in lysis buffer. Equal amounts of protein were subjected
to SDS-PAGE. After protein separation by electrophor-
esis, samples were transferred to Millipore Immobilon-P
membrane and immunoblotting with antibodies was
performed.
Migration assay
Migration assay was performed using the 24-well Boy-
den chambers (8 μm pores, BD Biosciences) as we pre-
viously described [17]. The cells were plated at a density
o f1×1 0
6 cells/100 μl of medium in the inserts, and
incubated for 3 h at 37°C followed by staining using the
Diff-Quick kit (Dade Behring). Pictures were taken with
a microscope and migrated cells were counted with
Image J software using 10 randomly chosen fields.
Overexpression of Epac1 or bARK-CT
Adenoviral overexpression of Epac1, bARK-CT or LacZ
was performed as we previously described [18]. bARK-
CT adenovirus was kindly provided by Dr. Koch. The
recombinant vector was introduced into human embryo-
nic kidney cells (HEK-293) to recover infectious adeno-
virus. Cells were infected with adenovirus for 24 h
followed by confirmation of overexpression of target
proteins.
Overexpression of Gb1 and Gg2 subunits
Plasmid constructs harboring Gb1o rG g2s u b u n i tw e r e
kindly provided by Dr. Simonds [24]. Plasmid transfec-
tion was performed as we previously described [22,23].
Briefly, 750 μl of serum- and antibiotics-free OPTI-
MEM was mixed with both 13.5 μlo fL i p o f e c t a -
mine2000 and 6.25 μl plasmid DNA. The mixture was
then diluted with 5 ml MEM supplement with 5% FBS
and gently overlaid onto the cells, followed by incuba-
tion for 16 h. The overexpression was confirmed by
western blot analyses, and the transfected cells were
used for cell migration or cytosolic Ca
2+ measurement
assays.
Data analysis and statistics
Statistical comparisons among groups were performed
using one factor ANOVA with Bonferroni post hoc test.
Statistical significance was set at the 0.05 level.
Results
Gbg inhibits Epac-induced cell migration in melanoma
We have previously demonstrated that Epac increases
melanoma cell migration by modification of heparan
sulfate [17]. In addition, since it has been reported that
Gbg plays a role in cell migration of endothelial cells
and breast cancer cells [4-6], we examined the effects of
Gbg on melanoma cell migration. We found that
mSIRK, a cell-membrane permeable activator of Gbg
[7], decreased basal cell migration only at the highest
dose (50 μM). In contrast, mSIRK inhibited Epac1 over-
expression-induced cell migration in a dose-dependent
manner (Figure 1a). These data suggest that the inhibi-
tory effect of Gbg is obvious under Epac-activated con-
ditions, but not clear under basal conditions (Figure 1a).
Gp(CH)2pp, a constitutively active GTP analogue which
dissociates Gbg from Ga, also inhibited Epac-induced
cell migration. In addition, mSIRK inhibited cell migra-
tion induced by 8-pMeOPT, an Epac-specific agonist,
suggesting that Gbg also inhibits cell migration induced
by endogenous Epac (Figure 1b). Further, we examined
the specificity of Gbg in the inhibition of Epac-induced
cell migration. Co-overexpression of Gb1 and Gg2 subu-
nits (Figure 1c), which is the major combination of Gbg
[25], inhibited Epac1-induced cell migration (Figure 1e).
By contrast, overexpression of bARK-CT (Figure 1d), an
inhibiting-peptide for Gbg [26], abolished the mSIRK’s
inhibitory effect (Figure 1e). These data suggest that
there is cross talk between Gbg and Epac, which affects
melanoma cell migration. Since activation of Epac was
achieved by artificial overexpression or the Epac-agonist
which does not exist in nature, we tested whether hor-
monal control of GPCR increases cell migration via
Epac. Stimulation of b-adrenergic receptor increased cell
migration in melanoma, and it was inhibited by ablation
of Epac1 (Figure 1f), suggesting that Epac increases cell
migration upon activation of hormone receptors.
Gbg inhibits Epac-induced Ca
2+ elevation
We next explored the mechanism by which Gbg inhibits
Epac-induced cell migration. Since our previous report
have shown that Epac1-induced cell migration is
mediated by Ca
2+ release from the ER [18], we examined
whether mSIRK affects Epac1-induced cytosolic Ca
2+
elevation. When cells were pretreated with mSIRK, but
not with L9A, 8-pMeOPT failed to increase Ca
2+ signal
(Figure 2a and 2b). In addition, co-overexpression of Gb1
and Gg2 also inhibited 8-pMeOPT-induced Ca
2+ eleva-
tion (Figure 2c). Further, inhibition of Gbg with bARK-
CT, or guanosine 5’-O-(2-thiodiphosphate) (GDPbS), a
GDP analogue that inactivates Gbg, restored 8-pMeOPT-
induced Ca
2+ elevation (Figure 2d and 2e). These data
suggest that Gbg inhibits Epac-induced Ca
2+ release.
Gbg activates Ca
2+ entry from the extracellular space
Since IP3 receptors are inactivated by prior cytosolic Ca
2+ elevation [19-21], we hypothesized that Ca
2+ eleva-
tion induced by Gbg inhibits Epac-induced Ca
2+ eleva-
tion. mSIRK, but not L9A, increased Ca
2+ signal in SK-
Mel-2 cells (Figure 3a and 3b). mSIRK-induced Ca
2+
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including WM1552C, a regional growth pattern primary
melanoma cell line (RGP), WM115, WM1361A,
WM3284, vertical growth pattern primary melanoma
cells (VGP), and SK-Mel-24, SK-Mel-187 and C8161,
metastatic melanoma cell lines (MM) (data not shown),
suggesting mSIRK’s effect on Ca
2+ is universal in differ-
ent types of melanoma. After the elevation of Ca
2+ sig-
nal by mSIRK, 8-pMeOPT did not show an additional
elevation of Ca
2+ signal (Figure 3b). GDPbSi n h i b i t e d
mSIRK-induced cytosolic Ca
2+ elevation, suggesting the
specificity of mSIRK for Gbg (Figure 3c). We next exam-
ined the source of Gbg-induced Ca
2+. When extracellu-
lar Ca
2+ was depleted by removal of Ca
2+ or by
addition of EGTA, a Ca
2+-chelating agent, mSIRK did
not increase Ca
2+ signal (Figure 3d and 3e, respec-
tively). By contrast, inhibition of IP3 receptors or ryano-
dine receptor did not affect mSIRK-induced Ca
2+ signal
(Figure 3f, g and 3h). Further, depletion of Ca
2+ store
in the ER with thapsigargin did not inhibit mSIRK-
induced Ca
2+ elevation (Figure 3i). Taken together,
these data suggest that Gbg induces Ca
2+ from the
extracellular space, but not from intracellular store.
Calmodulin is involved in Gbg-mediated effects on Epac-
induced Ca
2+ elevation/cell migration
Since IP3 receptor is known to be inactivated by Ca
2
+/calmodulin [19-21], we examined whether calmodulin
mediates Gbg’s inhibitory effect on Epac-induced Ca
2+
elevation. W-5, a calmodulin inhibitor, restored Epac-
mediated Ca
2+ s i g n a l ,a n dc e l lm i g r a t i o ne v e ni nt h e
presence of mSIRK (Figure 4a and 4c, respectively). In
order to identify Ca
2+ channel in which Gbg activates
Ca
2+ influx from the extracellular space, we tested Ca
2
+ inhibitors in mSIRK-induced Ca
2+ elevation. We then
found that, 4-methyl-4’ -[3,5-bis(trifluoromethyl)-1H-
Figure 1 Gbg inhibits Epac-induced cell migration. a) SK-Mel-2 cells were infected with adenovirus harboring LacZ or Epac1 followed by the
migration assay in the presence of mSIRK or Gp(CH2)pp (10 μM). mSIRK inhibited Epac1-induced melanoma cell migration. *, p < 0.05 vs. LacZ
control, #, p < 0.05 vs. Epac1 control. n = 4 except 5 and 10 μM of mSIRK (n = 2). b) Migration assay was performed in SK-Mel-2 cells in the
presence or absence of 8-pMeOPT (200 μM), L9A (20 μM) or mSIRK (20 μM). mSIRK, but not L9A, inhibited 8-pMeOPT-induced cell migration. n =
4. c and d) Following the termination of adenovirus harboring LacZ or Epac1, SK-Mel-2 cells were subjected to co-overexpression of Gb1 and
Gg2 subunits or bARK-CT. Western blot analyses showed increased expression of the target proteins. e) Migration assay was performed in SK-Mel-
2 cells. Co-overexpression of Gb1 and Gg2 inhibited Epac1-induced cell migration. Overexpression of bARK-CT restored Epac1-induced cell
migration even in the presence of mSIRK (20 μM). f) Ablation of Epac1 inhibits GPCR-induced cell migration in melanoma. SK-Mel-2 cells were
infected with lentivirus harboring Epac1- or control-shRNA as we previously described [18]. Migration assay was performed in the presence or
absence of isoproterenol (ISO) (100 μM), a b-adrenergic receptor agonist. Ablation of Epac1 inhibits both basal and ISO-induced cell migration. n
=4 .
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(YM58483), which is known as an antagonist for Ca
2
+-activated Ca
2+ channels (CRAC) [27] or canonical
transient receptor potential (TRP) channels [28], inhib-
ited mSIRK-induced Ca
2+ signal (Figure 4b). In addi-
tion, YM58483 attenuated Gbg’s inhibitory effect on
Epac-induced cell migration (Figure 4c). Since
YM583483 did not change basal cell migration (Figure
4c), Gbg-activation is necessary to inhibit Epac-induced
cell migration. In contrast, neither verapamil nor nifedi-
pine inhibit mSIRK-induced Ca
2+ (data not shown),
suggesting that dihydropyridine Ca
2+ channels are not
involved in Gbg-induced Ca
2+ signal. Put together, Gbg
inhibits Epac-induced Ca
2+ elevation, and cell migration
by Ca
2+/calmodulin pathway.
Discussion
In the present study, we demonstrated that Gbg inter-
feres with the Ca
2+ signaling evoked by Epac, leading to
an inhibition of Epac-induced cell migration. We found
that Gbg activates Ca
2+ entry from the extracellular
space, which inhibits Epac-induced cytosolic Ca
2+ ele-
vation, and cell migration. Calmodulin is presumably
involved in these Gbg’s effects. Since Gbg is a common
molecule located downstream of various GPCRs, our
findings would provide novel insights in terms of Ca
2+
signaling, cell migration, and cross talk of intracellular
signaling in melanoma (Figure 5).
We previously demonstrated that the expression of
Epac1 is increased in metastatic melanoma than in pri-
mary melanoma in human melanoma samples. In addi-
tion, overexpression of Epac1 enhanced melanoma
metastasis in mice [17]. These previous findings indicate
that Epac1 accelerates melanoma metastasis, and thus a
molecule that can inhibit Epac1 is a potential drug for
suppressing melanoma metastasis. The major mechan-
ism by which Epac1 enhances melanoma metastasis is,
at least in part, an increase of cell migration via the Ca
2+-dependent mechanism [18]. We demonstrated that
Epac activates the PLC/IP3 pathway, leading to the acti-
vation of IP3 receptor in the ER. Subsequently, Ca
2+
released from the ER modifies actin assembly, and as a
Figure 2 Gbg inhibits Epac-induced Ca
2+ elevation. SK-Mel-2 cells were subjected to Ca
2+ signal measurements. Arrows indicate addition of
8-pMeOPT (200 μM). a and b) SK-Mel-2 cells were pre-incubated with L9A (20 μM) or mSIRK (20 μM) for 5 min followed by the addition of 8-
pMeOPT. mSIRK, but not L9A, inhibited 8-pMeOPT-induced Ca
2+ elevation. c) 8-pMeOPT did not increase Ca
2+ signal in SK-Mel-2 cells with co-
overexpression of Gb1 and Gg2. d) 8-pMeOPT increased Ca
2+ signal in SK-Mel-2 cells with overexpression bARK-CT even in the presence of
mSIRK. e) When SK-Mel-2 cells were pretreated with the combination of mSIRK and GDPbs, 8-pMeOPT increased Ca
2+ signal.
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Epac-induced migration was inhibited by stimulation of
different types of GPCRs, i.e., b-adrenergic receptor,
lysophosphatidic acid receptor and endothelin receptor.
Since types of Ga subunit are different in these GPCRs
whereas Gbg is common in these receptors, we hypothe-
s i z e dt h a tG bg mediates the inhibition in Epac-induced
cell migration.
Although it is well known that Gbg regulates mem-
brane Ca
2+ channels in excitable cells, little attention
has been paid to its role in non-excitable cells including
cancer cells. A report demonstrated that Gbg activates
IP3 receptor via phospholipase C [29]; however, this is
not the case in melanoma because antagonists of IP3
receptors did not inhibit mSIRK-induced Ca
2+ elevation
(Figure 3f and 3g). Instead, we found that Gbg induces
Ca
2+ from the extracellular space in all melanoma cell
lines which we have tested in this study. Moreover, the
prior Ca
2+ elevation by Gbg inhibited Epac-induced Ca
2+ release, suggesting the crosstalk of Ca
2+ signaling
between Gbg and Epac. We also found that calmodulin,
an ubiquitously expressed calcium binding protein, pre-
sumably mediates this Gbg’s effect (Figure 4a). Since the
activity of IP3 receptor is reduced by cytosolic Ca
2+
Figure 3 Gbg induces Ca
2+ influx from the extracellular space. SK-Mel-2 cells were subjected to Ca
2+ signal measurements. a and b) SK-
Mel-2 cells were incubated with L9A (20 μM) or mSIRK (20 μM) followed by 8-pMeOPT stimulation (200 μM). mSIRK, but not L9A, increased Ca
2
+ signal. 8-pMeOPT failed to show an additional increase of Ca
2+ signal after mSIRK. c, d and e) mSIRK-induced Ca
2+ signal was inhibited by
pretreatment with GDPbS (100 μM) for 5 min (c), by Ca
2+ removal from the media (d) or by depletion of Ca
2+ in the extracellular space with
EGTA (5 mM) (e). SK-Mel-2 cells were subjected to Ca
2+ signal measurements. f, g and h) Inhibition of IP3 receptors with 2-APB (1 μM) (f) or
xestopongin C (1 μM) (g), and blocking of ryanodine receptor with ryanodine (10 μM) (h), did not inhibit mSIRK-induced Ca
2+ elevation. i)
mSIRK increases Ca
2+ signal SK-Mel-2 cells after depletion of Ca
2+ in the ER with thapsigargin (2 μM).
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receptor, it is tempting to speculate that calmodulin is
activated by Gbg-induced Ca
2+, leading to inactivation
of IP3 receptor.
A question remains unclear what Ca
2+ channel(s) is
(are) activated by Gbg. We demonstrated that YM58483
inhibits mSIRK-induced Ca
2+ elevation. YM58483 is
known to inhibit CRAC [27]and TRP channels [28], sug-
gesting involvement(s) of these receptors in Gbg-
induced Ca
2+ entry. Further vigorous experiments
including knockdown of CRAC or TRP channels are
necessary to elucidate the mechanism of Gbg-mediated
Ca
2+ influx. In addition, it is necessary to identify
which G-protein coupled receptor(s) is(are) related to
Gbg-induced Ca
2+ entry, and to further investigate
whether knocking down of a specific subtype(s) of Gb
or Gg subunit reduces melanoma cell migration, and
metastasis. Meanwhile, mSIRK inhibited Epac-induced
cell migration in a dose dependent manner whereas it
did not reduce basal cell migration with the exception
of the higher concentration (50 μM) (Figure 1a), sug-
gesting that mSIRK’s inhibition is obvious only when
Epac is activated. This is in accordance with our pre-
vious report showing that inhibition of IP3 receptor
reduces melanoma cell migration only under Epac-acti-
vated conditions [18].
Conclusion
In summary, the current study demonstrated the poten-
tial new cross talk pathway in melanoma in terms of Ca
2+ homeostasis and cell migration. We demonstrated
that there is interaction in Ca
2+ signaling between Gbg
and Epac in melanoma. The interaction evoked by Gbg
inhibited Epac-induced Ca
2+ elevation and cell migra-
tion via additional Ca
2+ influx from extracellular space.
We, thus, propose that Gbg-signaling inhibits the Epac-
induced cell migration via a Ca
2+-dependent mechan-
ism in melanoma.
Figure 4 Calmodulin is involved in Gbg’s inhibition on Epac-induced Ca
2+ elevation, and cell migration. a) mSIRK (20 μM) and 8-pMeOPT
(200 μM) were added in the presence of W-5 (100 μM) in SK-Mel-2 cells. W-5 restored 8-pMeOPT-induced Ca
2+ elevation even in the presence
of mSIRK. b) YM58483 (5 μM) inhibited mSIRK-induced Ca
2+ elevation in SK-Mel-2 cells. c) Cell migration assay was performed in SK-Mel-2 cells
in the presence or absence of 8-pMeOPT, mSIRK, W-5 or YM58483. W-5 and YM58483 restored Epac-induced cell migration even in the presence
of mSIRK. n = 4.
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are universal in other non-excitable cells including other
types of cancer.
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